Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 17.00 | 7.80% | 235.00 | 84,885 | 16:09:13 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 234.00 | 236.00 | 237.00 | 228.00 | 228.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 838M | USD 100.78M | USD - | - | 1.9B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:07 | UT | 5,822 | 235.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 21/3/2025 | 12:23 | ALNC |  IN BRIEF: Hutchmed China's Tazverik conditionally approved in China |
| 21/3/2025 | 10:00 | UK RNS | Hutchmed (China) Limited NMPA Conditional Approval for TAZVERIK® |
| 20/3/2025 | 14:31 | ALNC | IN BRIEF: Hutchmed highlights positive lung cancer test results |
| 20/3/2025 | 09:30 | UK RNS | Hutchmed (China) Limited Retirement of Independent Non-executive Directors |
| 20/3/2025 | 07:00 | UK RNS | Hutchmed (China) Limited HUTCHMED Highlights Savolitinib SAVANNAH Phase II |
| 19/3/2025 | 13:45 | UK RNS | Hutchmed (China) Limited Publication of Form 20-F |
| 19/3/2025 | 12:08 | ALNC | Hutchmed China celebrates kidney cancer treatment; swings to loss |
| 19/3/2025 | 11:00 | UK RNS | Hutchmed (China) Limited 2024 Final Results and Business Updates |
| 19/3/2025 | 07:00 | UK RNS | Hutchmed (China) Limited Phase II/III Study of Fruquintinib and Sintilimab |
| 14/3/2025 | 09:30 | UK RNS | Hutchmed (China) Limited Adoption of the 2025 Long Term Incentive Plan |
Hutchmed (china) (HCM) Share Charts1 Year Hutchmed (china) Chart |
|
1 Month Hutchmed (china) Chart |
Intraday Hutchmed (china) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/3/2025 | 00:45 | (Chi-Med)Hutchinson China Meditech Limited | 4,126 |
| 25/3/2022 | 17:25 | Hutchison Chi-Med (HCM) One to Watch | 3 |
| 23/7/2018 | 09:55 | Hutchison Chi-Med (HCM) One to Watch on Monday | 1 |
| 13/6/2017 | 06:54 | Hutchison China Meditech- CHARTS AND DISCUSSION | 74 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-03-27 16:35:07 | 235.00 | 5,822 | 13,681.70 | UT |
| 2025-03-27 16:06:56 | 235.00 | 7 | 16.45 | AT |
| 2025-03-27 16:06:56 | 235.00 | 36 | 84.60 | AT |
| 2025-03-27 16:06:56 | 235.00 | 6 | 14.10 | AT |
| 2025-03-27 16:05:08 | 235.00 | 202 | 474.70 | AT |
| Top Posts |
|---|
Posted at 27/3/2025 08:20 by Hutchmed (china) Daily Update Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 218p.Hutchmed (china) currently has 871,601,095 shares in issue. The market capitalisation of Hutchmed (china) is -. This morning HCM shares opened at 228p |
Posted at 22/3/2025 00:45 by lauders More good news from HCM and the share price not responding. Been an "opportunity cost" hold, but one day it may reward.HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma – First and only EZH2 inhibitor approved by the NMPA – – HUTCHMED’s fourth product, and its first approval in hematological malignancies – |
Posted at 19/3/2025 11:53 by 1jat Sales were slightly better than I expected, with the share of revenue from Takeda rising from 33% to 38% (maybe some pre-orders to beat Trump tariffs.The Inmagene reverse takeover of Ikena will leave HCM with a 3% stake in the enlarged entity. They will have a post tax profit of $400m in 2025 from the disposal….and yet still no reward for shareholders. |
Posted at 04/3/2025 17:12 by 1jat Dominant shareholder CKHH will be flush with cash later this year as it is negotiating the sale of its ports to Blackrock and others. The deal will generate about US$19bn for CKHH. Plenty of firepower if they want to take HCM private or support M&A. |
Posted at 21/2/2025 00:13 by mcmather 20 Feb 2025: HUTCHMED (HCM) Upgraded to Buy: Here's Why |
Posted at 13/2/2025 09:22 by 1jat Mcmather - sentiment towards HK/China is poor in the west. No doubt HK/China is sceptical of the value of western operations represented in HK companies. So CKHH gets a double negative view. CKHH as a conglomerate trades at a hefty discount - if you add the market value of its listed subs you get the mcap of the parent. One might think the logical answer is a break up and realisation of the value of the assets……There is little synergy within the CK group of companies for Hutchmed to exploit and it seems to have been on its own for a while with CKHH selling down to under 40%. Hutchmed seems to be inhabiting a nether world where it has grown into a commercial organisation, but its larger competitors are interested in smaller bolt on acquisitions. Eventually the mid sized companies will need to huddle together to avoid being preyed upon or accept they will be only a bit part player in the background. The Sovlep manufacturing issue is just the latest in a steady flow of mis-steps. I think it is time for Victor to make a trade in HCM. |
Posted at 12/2/2025 20:28 by mcmather Double yer money from here..."Feb. 11, 2025, 09:25 AM BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target" |
Posted at 14/1/2025 08:38 by waldron Press ReleaseHUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - Indication expands to include treatment-naïve patients - - The 2021 conditional approval in previously treated patients converted to full approval - Hong Kong, Shanghai & Florham Park, NJ - Tuesday, January 14, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alteration. The NMPA has also converted the prior conditional approval of ORPATHYS® in the previously treated patient population to full approval. The new label indication for ORPATHYS® will now include both treatment-naïve and previously treated patients in China. |
Posted at 12/12/2024 07:44 by lauders Good news again. Will it have any effect on the share price?Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR |
Posted at 17/10/2024 13:32 by 1jat Arguably both cash flow + and - lead to M&A - one as the major party and one as the minor party.There are a lot of biotechs in China and there are significant efficiencies possible across pipeline assets, sales and general administration. New money is hard to raise but mergers are likely to be encouraged by the mainland to build some national champions (globally China cos are not in the big pharma league - that should change). If CKHH is willing to back HCM issuing new equity or taking on some debt, then it should be possible for HCM to take the lead on some M&A deals and grow inorganically - that is how big Pharma got to be big rather than organic growth. Pre-commercial deals - will come with more uncertainty but the target will bring some cash and R&D capabilities. The main economies will come from pushing more volume through the factory and sales channels when the acquired products are approved. Commercial stage deals - Should generate value for both shareholders due to the large synergies…..ba I dont think HCM has the management to do a significant merger at the moment, so if they are to be on the front foot I would expect a new CEO and a strategy director to be appointed first. |
Posted at 14/11/2022 06:58 by lauders Nearly +20% in HK now! Come on HCM share price at least match that! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
